English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Coordination compounds of pentavalent antimony have been, and remain, the first-line drugs in leishmaniasis treatment for &gt;70 years. Molecular forms of Sb (V) complexes are commercialized as sodium stibogluconate (Pentostam ® ) and meglumine antimoniate (MA) (Glucantime ® ). Ever-increasing drug resistance in the parasites limits the use of antimonials, due to the low drug concentrations being administered against high parasitic counts. Sb 5+ toxicity provokes severe side effects during treatment. To enhance therapeutic potency and to increase Sb (V) concentration within the target cells, we decided to try a new active substance form, a hydrosol of Sb 2 O 5 ·nH 2 O nanoparticles (NPs), instead of molecular drugs.

Nanoscaled hydrated antimony (V) oxide as a new approach to first-line antileishmanial drugs